Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppression reduction in kidney transplant recipients with septic shock or acute respiratory failure
2024-518493-14-00Phase 3Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- Aug 2025
- Modality
- Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus, cyclosporine, everolimus, sirolimus, mycophenolate mofetil and 5 more in sepsis, septic shock, acute respiratory decompensation and 1 more (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Reduction in SOFA score ≥4 points at day 5. Planned start Aug 2025; status: authorised.
02
Drugs
tacrolimuscyclosporineeverolimussirolimusmycophenolate mofetil
03
Conditions
sepsisseptic shockacute respiratory decompensationkidney allograft rejection
Beyond the preview
Go deeper on 2024-518493-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518493-14-00.